US Bancorp DE lowered its position in Elanco Animal Health Incorporated (NYSE:ELAN – Free Report) by 11.2% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,715 shares of the company’s stock after selling 3,228 shares during the period. US Bancorp DE’s holdings in Elanco Animal Health were worth $419,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Sapient Capital LLC acquired a new stake in Elanco Animal Health in the fourth quarter valued at $2,046,000. Phocas Financial Corp. acquired a new position in Elanco Animal Health during the fourth quarter worth about $3,857,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in Elanco Animal Health during the first quarter worth about $1,226,000. Vanguard Group Inc. lifted its holdings in shares of Elanco Animal Health by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 49,468,637 shares of the company’s stock valued at $737,083,000 after purchasing an additional 467,196 shares in the last quarter. Finally, Bank of Nova Scotia acquired a new stake in shares of Elanco Animal Health in the fourth quarter valued at approximately $4,004,000. 97.48% of the stock is owned by institutional investors and hedge funds.
Elanco Animal Health Stock Down 1.7 %
ELAN stock opened at $12.81 on Friday. The company has a 50 day moving average price of $15.97 and a two-hundred day moving average price of $15.56. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.96 and a current ratio of 3.29. The stock has a market capitalization of $6.33 billion, a P/E ratio of -4.83, a PEG ratio of 1.29 and a beta of 1.42. Elanco Animal Health Incorporated has a one year low of $8.52 and a one year high of $18.80.
Elanco Animal Health (NYSE:ELAN – Get Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The company reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.26 by $0.08. The business had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.18 billion. Elanco Animal Health had a positive return on equity of 5.98% and a negative net margin of 29.83%. The business’s revenue for the quarter was down 4.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.45 earnings per share. As a group, sell-side analysts expect that Elanco Animal Health Incorporated will post 0.93 EPS for the current year.
Wall Street Analyst Weigh In
Several research analysts recently issued reports on ELAN shares. Piper Sandler cut their price objective on Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating for the company in a research report on Monday, July 1st. Barclays cut their price target on Elanco Animal Health from $23.00 to $21.00 and set an “overweight” rating for the company in a report on Friday, June 28th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $17.57.
Read Our Latest Research Report on Elanco Animal Health
Insider Buying and Selling at Elanco Animal Health
In related news, Director William F. Doyle acquired 15,000 shares of the business’s stock in a transaction dated Tuesday, May 21st. The shares were acquired at an average cost of $16.98 per share, for a total transaction of $254,700.00. Following the acquisition, the director now directly owns 76,330 shares in the company, valued at approximately $1,296,083.40. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.57% of the stock is owned by company insiders.
Elanco Animal Health Profile
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.
Read More
Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN – Free Report).
Receive News & Ratings for Elanco Animal Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Elanco Animal Health and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
